clinical response to  xxxd105xxx : results of a phase 3 study of intramuscular administration of  xxxd105xxx  in patients with chronic plaque psoriasis.  recognition of psoriasis as a t-cell-mediated immune disease has led to the development of various therapeutic approaches directed against the pathogenic t cells.  xxxd105xxx , a novel and selective biological recombinant protein, binds cd2 on t cells to block t-cell activation and proliferation and interacts with fcgammariii receptors on accessory cells to produce selective t-cell apoptosis.